BIOGRAPHICAL SKETCH

A. Positions and Honors

Positions and Employment

1983-1986            Commonwealth Scholar, University of Manchester, England

1986-1989            Lecturer, Faculty of Pharmacy, Obafemi Awolowo University, Nigeria

1986-1993            Senior Lecturer, Faculty of Pharmacy, Obafemi Awolowo University, Nigeria

1993-  present      DAAD Fellow, Institute of Pharmaceutical Technology and Biopharmaceutics, University of   

                                Muenster, Germany

1994 -1996           NIH (Forgarty International Center) Post Doctoral Fellow, University of Utah

1996 -1997           Research Associate, Department of Pharmaceutics & Bioengineering, University of Utah

1998 - 2003           Assistant Professor of Pharmaceutics, School of Pharmacy, Howard University

2003 -  present      Associate Professor of Pharmaceutics, School of Pharmacy, Howard University

Other Experience and Professional Membership

1994-Present: Member of Controlled Release Society

1998-Present: Scientific Reviewer to ten scientific journals:

2002-Present: Pharmacist on Call: Bioterrorism Preparedness and Response Plan (Government of the District

                          of Columbia: The District of Columbia Department of Health and the Board of Pharmacy).

2002-Present: Member Sigma Xi, The National Research Society (USA)

2002-Present: Member American Chemical Society

2003-Present: NIH Grant Review Consultancy
 

(1) Special Emphasis Panel  (ZRG1 SSS-O 12 B, Small Business Cardiovascular and Pharmacology: March , 2003); (2) ZRG1 HP (10) B, June 2003; (3) Biomedical Research Review Subcommittee (NIH/NIAAA) Council AA-1, October 2003; (4) Special Emphasis Panel  ZRG1 SSS-O (10) B Small Business Cardiovascular and Pharmacology: November, 2003);  (5) NIH/NIDA RFP N43DA-4-7741 (Nanoscience-Based Design of Therapies for Substance Abuse Treatment), January 28, 2004; (6) Cardiovascular Science Small Business Activity (Special Emphasis Scientific Review Group : ZRG1 CVS-H 10 B, ZRG1 CVS SBIR, March 18-19, 2004); (7) N44DA-5-7741 (Topic 064) (Oral Buprenorphine Nanoparticle Formulation – Phase II SBIR –Topic 064 Contract Proposal): HHS Procurement N44DA-5-7741 (Topic 064). May 11, 2005); (8) Xenobiotic Disposition and Action (XNDA) Study Section: Digestive Sciences Integrated Review Group (June 7-8, 2006); (9) Technology Development Special Emphasis Panel (ZRG1 F14A 20L. June 29-30, 2006 ;(10) New Jersey Department of H & Senior Services Cancer research Funding Initiative New Jersey Cancer Development

Awards (NJDRDA) January 2009; (11) 2009/05 ZGM1 MBRS-X (CH) MBRS SCORE Applications

2003-Present: Member of the Education Committee of the Controlled Release Society

Honors

Distinguished Faculty Author, President and Provost, Howard University 1998-2000; 200-2001; 2001-2002; 2002-2003; 2004-2005; 2005-2006, 2006-2007, 2007-2008, 2008-2009: Recognition and Award by Howard University under Presidential Merit Superior Performance Awards:2000-2001, 2002, 2003, 2004, 2006; 2007, 2008, 2009

B. Research Interests

• Biopharmaceutical Applications of Nanotechnology

• Controlled Drug Delivery and Drug Targeting

• Pharmacokinetics in Pharmaceutical Dosage Form Design

• Biopharmaceutics

• Pulsatile Drug Delivery Systems

• Biomaterials

• Drug Formulation and Stability Studies
   

C. Selected Peer-Reviewed Publications In Chronological Order

1.  Patent : “Novel  pHSensitive Hydrogels with Adjustable  Swelling Kinetics for Colon-Specific Delivery of

     Peptides and Proteins” Patent Number:WO9801421 (Published on 01/15/1998). Inventors: Jindrich Kopecek, Pavla Kopeckova, 

     Emmanuel O. Akala, Ping-Yang Yeh, and Karel Ulbrich.

2. E. O. Akala, P. Kopeckova and J. Kopecek, Novel pH Sensitive Hydrogels with Adjustable Kinetics of

    Swelling. Biomaterials 19; 1037 - 1047(1998).

3. R. Groning, S. Weyel, E. Akala, E. Minkow and N. Lambow. Computer-Controlled Release of Oxprenolol

    from Capsules Using Gas Producing Cells and Electronic Circuits, Pharmazie 54(7); 510-513 (1999).

4. W. Yin, E. Akala, and R. Taylor, Design  of naltrexone-loaded hydrolyzable crosslinked nanoparticles

     International Journal of Pharmaceutics, 244(1-2); 9-19(2002)

5. Emmanuel O. Akala, Oluchi Elekwachi, Vantoria Chase, Hausalynn Johnson, Marjorie Lazarre, Kenneth

    Scott. “Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery” Drug   

    Development Industrial Pharmacy, 29 (No 4);  375-386(2003)

6. Akala, E.O. “Oral Controlled Release Solid Dosage Forms” in Theory and Practice of Contemporary

    Pharmaceutics, Edited by Tapash K. Gosh and Bhaskara R Jasti (CRC Press LLC, Boca Raton, FL). In Press (ISBN:   

     0415288630, March 1, 2004)

7.  Gaofeng Pan, Yahia Lemmouchi, Oladapo Bakare and Emmanuel O. Akala  Studies on

     PEGylated and Drug-Loaded PAMAM Dendrimers Journal of Bioactive and Compatible Polymers 20;113-128 (2005)

8. Emmanuel O. Akala,  “Chapter 7.3: Effect of Packaging on Stability of Drugs and Drug Products” in

    Pharmaceutical Manufacturing  Handbook: Regulations and Stability (2008). Edited by Shayne Cox Gad.

    Published by John Wiley & Sons, Inc. Hoboken, New Jersey. ISBN: 978-0-470-25959-7

9. E. O. Akala “Strategies for Transmembrane Passage of Polymer-Based Nanostructures” in Polymer-Based

    Nanostructures: Medical Applications (A Book In The Series “Nanoscience and Nanotechnology”) Published By The Royal    

   Society of Chemistry. The Book Series is Edited By Nobel Laureate Professor Sir Harry Kroto from The University of Sussex,  

   Professor Paul O'Brien from The University of Manchester and Professor Harold Craighead from Cornell University (In Press)

10. E. Akala; H. Wang, R. Zhang; R. Taylor and A. Adedoyin  Disposition of Naltrexone after Intravenous Bolus Administration in  
       Wistar Rats, Low Alcohol Drinking Rats and High Alcohol Drinking  Rats: Neuropsychobiology 2008;58:81-90

D. Research Support: Ongoing Support

(a) PI: Emmanuel O. Akala: NIH/National Cancer Institute: “Biodegradable Polymeric Nanosphere Drug Delivery System For  

      Cancer Chemotherapy" (Grant #: 1 SC2 CA138179-01) 2008-2011 $333,000

(b) 1 C06 RR 020608-01 Lecca (PI)                09/30/2004-08/31/2009 NIH/NCRR ($3,519, 000)

     Renovation of the First and Ground Floors in the School of Pharmacy to House the Center for Drug Research and  

      Development. To facilitate collaborative research efforts in the areas of drug research and development

      Role: Co-PI (Emmanuel O. Akala)

(c) Howard University Fund for Academic Excellence Grants Program, Cycle 14, Travel Grant Proposal Akala (PI) 07/01/ 2008-

      06/30/2009

      Visit to the Chao Center for Industrial Pharmacy and Workshop on Statistical Experimental Design Role: PI

Completed Research Support

(a) 1 R21 AA13407 Akala (PI) 02/28/2002-08/30/2006 NIH/NIAAA

     Controlled Drug Delivery System for Naltrexone:  $450,000 (b) W. M. Keck Foundation for Keck Center for the Design of  

     Nanoscale Materials for Molecular Recognition at Howard University: $1,000,000 for Five Research Groups (Akala Co-PI)  

    01/02/2002 -12/31/2004